PSTC 1201
Alternative Names: PSTC-1201Latest Information Update: 28 Nov 2025
At a glance
- Originator BioAge Labs
- Class Obesity therapies
- Mechanism of Action Apelin receptor agonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Obesity
Most Recent Events
- 20 Oct 2025 Early research in Obesity in USA (Parenteral), prior to October 2025 (BioAge labs pipeline, October 2025)
- 20 Jun 2025 Preclinical trials in Obesity in USA (PO)
- 20 Jun 2025 Pharmacodynamics data from the preclinical studies in Obesity presented at the 85th Annual Scientific Sessions of the American Diabetes Association (ADA-2025)